Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139763 · ClinicalTrials.gov registry record · Phase 3
US Inhaled Insulin Therapeutic Choice Questionnaire Study
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT00139763: Completed Phase 3 study of Diabetes Mellitus, Type 2, sponsored by Pfizer.
NCT00139763 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by Pfizer. The registered enrollment target is 740 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00139763, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments. This study will also ask if patients with uncontrolled type 2 diabetes currently managed on diabetes pills + once daily insulin will choose as the next treatment choice to take insulin multiple times a day if inhaled insulin were available in addition to all currently available treatments, compared with if inhaled insulin was not available as part of currently available treatments.
Conditions Studied
Interventions
- PROCEDURE Educational Materials
Study Locations (20)
Arizona
- Pfizer Investigational Site - Chandler
- Pfizer Investigational Site - Mesa
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tempe
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - San Diego
Delaware
- Pfizer Investigational Site - Newark
- Pfizer Investigational Site - Wilmington
Florida
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Jacksonville
Idaho
- Pfizer Investigational Site - Hayden
- Pfizer Investigational Site - Nampa
Colorado
- Pfizer Investigational Site - Colorado Springs
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Illinois
- Pfizer Investigational Site - Gurnee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00139763 record still lists
NCT00139763 is an interventional study that assigns participants to a tested intervention. The registered 740 participants enrollment target is mid-sized for trials with a published cap, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Educational Materials is the first listed.
NCT00139763 names 20 study sites across 12 states, led by Arizona, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT00139763 about?
NCT00139763 is a clinical study titled "US Inhaled Insulin Therapeutic Choice Questionnaire Study". This is a questionnaire based study (no study drug is involved) that asks if more patients with uncontrolled type 2 diabetes on diabetes pills will choose insulin as the next treatment choice if inhaled insulin were available in addition to all currently available treatments, compared with if inhale...
What is the current status of trial NCT00139763?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 740 participants. The study started on 2005-07. Estimated completion is 2006-03.
What conditions does trial NCT00139763 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00139763?
The interventions under investigation include: Educational Materials (PROCEDURE).
Who is sponsoring clinical trial NCT00139763?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00139763 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00139763's enrollment target sits among peer trials
740 52nd of 348 higher than 297 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- NCT06172478 · 740 participants · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia